Compare LUMN & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUMN | RGEN |
|---|---|---|
| Founded | 1968 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.2B |
| IPO Year | 1972 | N/A |
| Metric | LUMN | RGEN |
|---|---|---|
| Price | $8.07 | $160.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $5.73 | ★ $170.90 |
| AVG Volume (30 Days) | ★ 13.7M | 724.0K |
| Earning Date | 02-03-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $12,690,000,000.00 | $707,890,000.00 |
| Revenue This Year | N/A | $17.84 |
| Revenue Next Year | N/A | $12.57 |
| P/E Ratio | ★ N/A | $6,185.26 |
| Revenue Growth | N/A | ★ 11.74 |
| 52 Week Low | $3.01 | $102.97 |
| 52 Week High | $11.95 | $182.52 |
| Indicator | LUMN | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 51.46 |
| Support Level | $8.13 | $156.31 |
| Resistance Level | $8.96 | $165.02 |
| Average True Range (ATR) | 0.53 | 4.73 |
| MACD | -0.03 | -1.26 |
| Stochastic Oscillator | 19.80 | 24.04 |
Lumen Technologies is one of the largest telecommunications carriers serving global enterprises. The merger with Level 3 in 2017 and the 2022 divestiture of much of its local phone business in rural areas and small markets shifted the company's operations away from the legacy consumer business and toward enterprises services, which account for about 75% of revenue. Lumen offers businesses a full suite of communications services, providing colocation and data center services, data transportation, phone service, and internet access. Lumen has announced the sale of its remaining consumer fiber network to AT&T, which will further shift its focus to enterprise customers.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.